Skip to main content

Lynch Brian Joseph's Form 4 filing

Madrigal Pharmaceuticals, Inc. (MDGL) · filed Jan 6, 2023

Accession no.
0000899243-23-001137
Filed
Jan 6, 2023
Trade date
Jan 3, 2023
Filing delay
3 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.68M. It was filed 3 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lynch Brian JosephCIK 0001776196Officer (SVP and General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 3, 2023Common StockMOption exerciseAcquired+13,000$91.79+$1,193,27013,000Direct
Jan 3, 2023Common StockSSaleDisposed−600$277.91F3−$166,74612,400Direct
Jan 3, 2023Common StockSSaleDisposed−400$279.10F4−$111,64012,000Direct
Jan 3, 2023Common StockSSaleDisposed−1,800$280.66F5−$505,18810,200Direct
Jan 3, 2023Common StockSSaleDisposed−2,656$281.97F6−$748,912.327,544Direct
Jan 3, 2023Common StockSSaleDisposed−2,628$282.97F7−$743,645.164,916Direct
Jan 3, 2023Common StockSSaleDisposed−1,549$283.85F8−$439,683.653,367Direct
Jan 3, 2023Common StockSSaleDisposed−829$285.15F9−$236,389.352,538Direct
Jan 3, 2023Common StockSSaleDisposed−2,038$285.74F10−$582,338.12500Direct
Jan 3, 2023Common StockSSaleDisposed−400$286.62F11−$114,648100Direct
Jan 3, 2023Common StockSSaleDisposed−100$287.86F12−$28,7860Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 3, 2023Common StockMOption exerciseDisposed−13,000$0.00$012,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.90 to $277.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.06 to $279.38, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.22 to $281.16, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.32 to $282.30, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.41 to $283.33, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.42 to $284.21, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $284.50 to $285.49, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.50 to $286.29, inclusive.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.61 to $286.63, inclusive.

Referenced by the price of 1 transaction in Table I.

F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.86 to $287.86, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)